Explore ›
Finding
Finding
improvement
In patients with NAFLD and diabetes, metformin use was associated with a 22% lower risk of hepatocellular carcinoma compared with no diabetes medication, independent of glycemic control.
| Effect size | HR 0.77 |
| CI | 95% CI 0.65-0.90 |
| Comparator | no diabetes medication |
| Effect summary | improvement; HR 0.77; CI: 95% CI 0.65-0.90 |
| Effect modifiers | [{"modifier": "liver fibrosis severity (FIB-4)", "interaction_p": "", "direction": "amplifies", "stratum_details": "FIB-4 >=1.45: HR 5.33 (95% CI 4.73-6.00) for HCC vs FIB-4 <1.45; metformin benefit more pronounced in high-risk fibrosis patients", "plain_language": "Metformin's protective effect may be especially relevant for patients with more advanced liver fibrosis, who face much higher HCC risk overall", "annotation_notes": "FIB-4 was the strongest predictor of HCC risk in the model. The Discussion suggests metformin's chemo-preventive effect is especially important among those at risk of advanced fibrosis."}] |
Connected entities
Interventions
Conditions
Outcomes
Populations
Source
PMC9107529
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease